CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Dermabase.it
Gastrobase.it

Angiotensin converting enzyme inhibitors and risk of lung cancer


The aim of a population-based cohort study was to determine whether the use of angiotensin converting enzyme inhibitors ( ACEIs ), compared with use of angiotensin receptor blockers, is associated with an increased risk of lung cancer.

A cohort of 992 061 patients newly treated with antihypertensive drugs during the period 1995-2015 was identified and followed until 31 December 2016.

Cox proportional hazards models were used to estimate adjusted hazard ratios with 95% confidence intervals of incident lung cancer associated with the time varying use of ACEIs, compared with use of angiotensin receptor blockers, overall, by cumulative duration of use, and by time since initiation.

The cohort was followed for a mean of 6.4 ( SD 4.7 ) years, generating 7952 incident lung cancer events ( crude incidence 1.3 [ 95% confidence interval 1.2 to 1.3 ] per 1000 person years ).

Overall, use of ACEIs was associated with an increased risk of lung cancer ( incidence rate 1.6 v 1.2 per 1000 person years; hazard ratio [ HR ] 1.14, 95% confidence interval 1.01 to 1.29 ), compared with use of angiotensin receptor blockers.

Hazard ratios gradually increased with longer durations of use, with an association evident after five years of use ( HR=1.22, 1.06 to 1.40 ) and peaking after more than 10 years of use ( 1.31, 1.08 to 1.59 ).

Similar findings were observed with time since initiation.

In this population-based cohort study, the use of angiotensin converting enzyme inhibitors was associated with an increased risk of lung cancer.
The association was particularly elevated among people using angiotensin converting enzyme inhibitors for more than five years.
Additional studies, with long term follow-up, are needed to investigate the effects of these drugs on incidence of lung cancer. ( Xagena )

Hicks BM et al, BMJ 2018;363:k4209

XagenaMedicine_2018



Indietro